Drugs & Targets Adaptimmune receives Orphan Drug Designation for SPEAR T-cells targeting MAGE4-A in soft tissue sarcoma September 13, 2019Vol.45 No.34
Drugs & Targets BioXcel receives Orphan Drug Designation for BXCL701 in AML September 13, 2019Vol.45 No.34
Clinical Roundup IMFINZI is first immunotherapy to show OS benefit, improved, durable responses in extensive-stage SCLC September 13, 2019Vol.45 No.34
Clinical Roundup Pooled five-year survival results show OS advantage for Opdivo in advanced NSCLC September 13, 2019Vol.45 No.34
Clinical Roundup LOXO-292 shows 68% ORR, sustained durability in heavily pretreated RET fusion-positive NSCLC September 13, 2019Vol.45 No.34
Clinical Roundup ASTRO guideline clarifies role of radiation therapy in pancreatic cancer treatment September 13, 2019Vol.45 No.34
Clinical Roundup Study shows higher risk of death in patients with CV conditions who receive novel oral prostate cancer therapies September 13, 2019Vol.45 No.34
In Brief DeAngelis named MSK physician-in-chief, chief medical officer September 13, 2019Vol.45 No.34
In Brief Bondy named chair of Stanford Epidemiology and Population Health Department September 13, 2019Vol.45 No.34
In Brief Farrar named CEO at Ohio State James Cancer Hospital and Solove Research Institute September 13, 2019Vol.45 No.34
